Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

Completed 300 enrolled Intermountain Health Care, Inc. Abbott · collab Merck Sharp & Dohme LLC · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of \<200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.

Timeline

Start: 2002-08
Primary completion: —
Completion: 2006-09

Outcome

Missed primary endpoint

paper At 12 weeks, median hsCRP was significantly reduced (-14.6%, p = 0.004) from baseline, but the effect did not differ between treatments. PMID 16843192 ↗

paper Combination therapy was no more effective than either form of monotherapy. PMID 16843192 ↗

Publications

Results Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006 Jul 18;48(2):396-401. doi: 10.1016/j.jacc.2006.05.009. Epub 2006 May 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fenofibrate	Small molecule	160 mg	—
Subject	Simvastatin	Small molecule	20 mg	—